[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rod-cone-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rod-cone-dystrophy":114},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,76,157,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100619218","brain-stimulation-effects-on-orientation-and-mobility-skills-in-adults-with-vision-impairment-100619218",false,"NCT07341763","Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments","Inclusion Criteria:\n\n* Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling.\n* Have binocular visual acuity or best corrected binocular visual acuity no worse than 6\u002F12 or 20\u002F40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance.\n* Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent.\n* Have read and fully comprehends the information in the consent letter.\n* Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule.\n\nExclusion Criteria:\n\n* Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study.\n* Have been diagnosed with dementia or self-reported dementia with no formal diagnosis.\n* Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis.\n* Have been diagnosed with physical or motor impairments resulting in walking and\u002For balancing issues or self-reported physical or motor impairments resulting in walking and\u002For balancing issues with no formal diagnosis.\n* Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and\u002For mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and\u002For mobility with no formal diagnosis.\n* Are unable to follow the researcher's instructions.\n* Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study.\n* Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and\u002For their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable.\n* Have severe hearing impairment.\n* Are pregnant or trying to get pregnant.\n* Fit any of the typical contraindicators for brain stimulation. See contraindicator section below.\n\nFor all participants the contraindications for brain stimulation are:\n\n* Diagnosed with epilepsy or have previously experienced an epileptic seizure.\n* Implanted medication pump or implanted electronic device, including defibrillator or pacemaker.\n* Any metal implants in the head (excluding tooth fillings).\n* Active electric implants anywhere in the body (especially the head region).\n* On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia.\n* Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face.\n* Recurring headaches.\n* Previous head injury or skull fracture or head\u002Fbrain surgery.\n* Heart disease, neurological condition, or a history of cardiac or neurological surgery.\n* Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.",[26,27,28,29,30,31,32,33,34,35,36],"Retinitis Pigmentosa (RP)","Rod Cone Dystrophy","Visually Impaired Persons","Peripheral Visual Field Defect of Both Eyes","Low Vision, Both Eyes","Vision Loss Partial","Orientation","Mobility Difficulty","Mobility Limitation","Mobility and Independence","Glaucoma",[26,38,39,28,29,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Rod Cone dystrophy","Advanced Glaucoma","Low Vision, Both eyes","Brain stimulation","tES","tRNS","hf-tRNS","transcranial electrical stimulation","transcranial random noise stimulation","high-frequency transcranial random noise stimulation","Long white cane","white cane","mobility cane","walking","orientation and mobility","orientation","mobility","low vision","vision loss partial","occipital pole","primary visual cortex","V1","neuroplasticity","mobility difficulty","mobility limitation","mobility and independence","RECRUITING","2026-06-30",{"date":67,"type":68},"2026-07-01","ACTUAL",{"date":67,"type":20},{"date":71,"type":20},"2027-08-31",{"name":73,"class":74},"University of Waterloo","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":119,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":75},"100242565","inherited-retinal-degenerative-disease-registry-100242565","NCT02435940","Inherited Retinal Degenerative Disease Registry","Foundation Fighting Blindness My Retina Tracker Registry","MRTR","Inclusion Criteria:\n\n* Diagnosed with an inherited retinal degenerative disease OR\n\nExclusion Criteria:\n\n* Glaucoma only\n* Diabetic retinopathy only\n* Non-retinal disease\n* Not heritable retinal disease",true,{"count":86,"type":20},20000,"20 Years","OBSERVATIONAL","The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.",[91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118],"Eye Diseases Hereditary","Retinal Disease","Achromatopsia","Bardet-Biedl Syndrome","Bassen-Kornzweig Syndrome","Batten Disease","Best Disease","Choroidal Dystrophy","Choroideremia","Cone Dystrophy","Cone-Rod Dystrophy","Congenital Stationary Night Blindness","Enhanced S-Cone Syndrome","Fundus Albipunctatus","Goldmann-Favre Syndrome","Gyrate Atrophy","Juvenile Macular Degeneration","Kearns-Sayre Syndrome","Leber Congenital Amaurosis","Refsum Syndrome","Retinitis Pigmentosa","Retinitis Punctata Albescens","Retinoschisis","Rod-Cone Dystrophy","Rod Dystrophy","Rod Monochromacy","Stargardt Disease","Usher Syndrome",[120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147],"inherited retinal degenerative disease","retinitis pigmentosa","Usher","Leber","Bardet-Biedl","Batten","Best","cone dystrophy","cone-rod dystrophy","choroideremia","congenital night blindness","enhanced s-cone","cone monochromacy","Goldmann-Favre","Kearns-Sayre","Refsum","retinoschisis","rod-cone dystrophy","rod dystrophy","rod monochromacy","Sorsby pseudoinflammatory dystrophy","stargardt","achromatopsia","juvenile inherited macular degeneration","cone dichromacy","cone trichromacy","Charcot-Marie-Tooth","albipunctate dystrophy","2026-05-18",{"date":150,"type":68},"2026-05-19",{"date":152,"type":4},"2014-06",{"date":154,"type":20},"2037-06",{"name":156,"class":74},"Foundation Fighting Blindness",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":163,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":184},"100466567","adaptive-optics-imaging-of-outer-retinal-diseases-100466567","NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases","Inclusion Criteria:\n\n1. Are 21 years of age or older,\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),\n3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and\n4. Have been diagnosed with outer retinal disease or condition (Cohort 2).\n\nExclusion Criteria:\n\n1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),\n2. Have visual correction outside of the range +4 diopters (D) to -8 D,\n3. Have a history of adverse reaction to mydriatic drops,\n4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or\n5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH\u002FNEI AIs.","21 Years",{"count":165,"type":20},100,"The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.",[168,169,111,170,171,172,100,173,27,115],"Retinal Degeneration","Age-Related Macular Degeneration","Hydroxychloroquine Retinopathy","Usher Syndromes","Late-Onset Retinal Degeneration","Cone Rod Dystrophy","2026-05-06",{"date":176,"type":68},"2026-05-08",{"date":178,"type":68},"2021-08-27",{"date":180,"type":20},"2028-09-30",{"name":182,"class":183},"Food and Drug Administration (FDA)","FED",2,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":198,"conditions":199,"keywords":204,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":5},"100576757","phase-1-a-study-to-investigate-the-safety-of-opct-001-in-adults-who-have-primary-photoreceptor-disease-clarico-100576757","NCT06789445","A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)","A Phase 1\u002F2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease","CLARICO","Key Inclusion Criteria:\n\n* Confirmed genetic diagnosis of primary photoreceptor (PR) disease\n* Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.3. BCVA at Screening for Phase 2: ETDRS letter score between 20 to 60, inclusive.\n* Retinal structure examination in the study eye demonstrating regions suitable for cell administration.\n\nKey Exclusion Criteria:\n\n* Clinically relevant, active ocular inflammation or infection\n* Glaucoma or other significant optic neuropathy\n* Diabetic macular edema or diabetic retinopathy\n* Clinically significant cystoid macular edema\n* In phakic participants: Spherical equivalent refractive error of greater than 8.00 diopters myopia\n* Ocular surgery ≤3 months before Screening\n* Monocular vision (ie, no light perception in the fellow eye)\n* Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated.\n* Any current and active infection (bacterial\u002Fviral\u002Ffungal) that could put the participant at risk from immunosuppression\n* History of any cell therapy, gene therapy, or retinal implant at any time\n* Previously received a bone marrow or solid organ transplant",{"count":194,"type":20},54,[196,197],"PHASE1","PHASE2","Study OpCT-001-101 is a Phase 1\u002F2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.",[200,26,118,201,114,202,168,203,101],"Primary Photoreceptor Disease","Inherited Retinal Disease (IRD)","Rod-Cone Disease","Cone-Rod Disease (C-RD)",[191,205,206,207,118,111,208,209,210,211],"Photoreceptor cells","Cell Therapy","Cellular Therapy","Inherited retinal disease (IRD)","Primary Photoreceptor disease (PPD)","Rod-Con Disease (R-CD)","Cone-Rose disease (C-RD)","2026-04-07",{"date":214,"type":68},"2026-04-13",{"date":216,"type":68},"2025-03-10",{"date":218,"type":20},"2030-10",{"name":220,"class":221},"BlueRock Therapeutics","INDUSTRY"]